UTHR · United Therapeutics Corp
Price
Snapshot
50 fields · last close| Market Cap | $21.89B |
| P/E | 16.03 |
| Float | 41.58M |
| Beta | 0.51 |
| Volatility | 12.8% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 83 |
| Price | 488.92 |
| Change | −0.27% |
| Prev Close | 490.24 |
| Open | 494.09 |
| Day Low | 477.06 |
| Day High | 494.09 |
| Avg Vol | 1 |
| Avg $ Vol | $264.3M |
| 52W High | 609.35 |
| 52W Low | 375.61 |
| 52W Pos | 48.5% |
| From High | −19.76% |
| From Low | +30.17% |
| Max DD 1Y | −17.85% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −4.91% |
| SMA 50 | −7.19% |
| SMA 200 | −6.58% |
| RSI (14) | 35.6 |
| Vol 30D | 24.8% |
| Vol 90D | 23.5% |
| 1Y Range | 376–609 |
| Daily bars | 506 |
| Perf Week | −7.14% |
| Perf Month | −5.54% |
| Perf Quarter | −10.49% |
| Perf Half Y | +1.07% |
| Perf Year | +25.24% |
| Perf YTD | −1.57% |
| Prev Day | −0.27% |
| Clavix | A- |
| Debt / Eq | 0.00 |
| Curr Ratio | 6.60 |
| Int Cover | 15.0× |
| FCF Margin | 36.4% |
| Rev Growth | −1.9% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 1 / 35 |
Clavix risk grade
regraded every trading dayUTHR grades A-, 83 of 100. Steadiest on Price Stability (68), most exposed on News Sentiment (61, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 1 of 35 in Biotechnology by Clavix score.
How rough the ride is
| UTHR | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.51 | 0.50 |
| Volatilityannualized | 12.8% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −17.8% | — |
| Typical daily movemedian absolute daily change | 1.07% | — |
| Days beyond ±3%of the last 252 sessions | 146% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| UTHR | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.51 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| UTHR | |
|---|---|
| 1 week | −7.1% |
| 1 month | −5.5% |
| Year to date | −1.6% |
| 1 year | +25.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| UTHR | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 29 Jul |
| Average score0 most bearish, 100 most bullish | 60 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 4 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| UTHR | |
|---|---|
| Revenue growthyear over year | −1.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | UTHR | Sector spread | Median |
|---|---|---|---|
| Beta | 0.51 | 0.50 | |
| Volatility | 12.8% | 13.2% | |
| P/E | 16.03 | 22.77 | |
| Debt / equity | 0.00 | 0.24 | |
| Current ratio | 6.60 | 3.73 | |
| FCF margin | 36.4% | 29.1% | |
| Interest coverage | 15.0× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openThe FDA accepted United Therapeutics' application to expand the label of its drug Tyvaso to include treatment of idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Acceptance means the FDA will now formally review the request, which is backed by study data showing improved lung function and reduced clinical worsening in patients.
Swedish insurance company Skandia bought 36,400 shares of United Therapeutics during the second quarter, valued at about $19.70 million and equal to roughly 0.08% of the company. The purchase was disclosed through a 13F filing, which is the quarterly SEC report large investment managers are required to file listing their stock holdings.
Legal & General Group Plc disclosed in a routine SEC filing that it bought 207,093 shares of United Therapeutics in the second quarter, opening a brand-new position worth about $112.2 million. A 13F is the quarterly form large investment managers must file showing what they own, so this tells us what one institutional investor held at the end of June rather than something UTHR did.
Caisse de depot et placement du Quebec, a large Canadian pension fund manager, disclosed in a recent SEC filing that it bought a new position in United Therapeutics during the second quarter, purchasing 284,783 shares worth about $154.30 million.
Hedge fund Man Group plc bought 134,890 shares of United Therapeutics (UTHR), worth about $73.09 million, during the second quarter, according to its SEC filing. The article text is cut off and provides no further details.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| INCY | Incyte Corp | B+ | $25.95B | 16.10 | 0.78 | Compare |
| INSM | Insmed Inc | C- | $27.66B | — | 0.82 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $16.91B | 19.37 | 0.38 | Compare |
| NBIX | Neurocrine Biosciences Inc | B | $16.10B | 22.77 | 0.36 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $14.74B | — | 0.96 | Compare |
| EXEL | Exelixis Inc | B+ | $14.65B | 17.10 | 0.48 | Compare |
| BIIB | Biogen Inc | B+ | $33.17B | 39.72 | 0.12 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C | $35.39B | 44.28 | 0.34 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.